Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ONCODESIGN
  6. Summary
    ALONC   FR0011766229

ONCODESIGN

(ALONC)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
10.72(c) 10.6(c) 10.46(c) 10.44(c) 10.32 Last
2 419 4 920 7 474 3 352 2 254 Volume
-0.19% -1.12% -1.32% -0.19% -1.15% Change
More quotes
Estimated financial data (e)
Sales 2021 32,0 M 37,7 M 37,7 M
Net income 2021 -1,15 M -1,35 M -1,35 M
Net Debt 2021 1,73 M 2,03 M 2,03 M
P/E ratio 2021 -27,5x
Yield 2021 -
Sales 2022 52,3 M 61,6 M 61,6 M
Net income 2022 2,83 M 3,33 M 3,33 M
Net cash position 2022 7,81 M 9,20 M 9,20 M
P/E ratio 2022 9,55x
Yield 2022 -
Capitalization 71,3 M 83,9 M 83,9 M
EV / Sales 2021 2,28x
EV / Sales 2022 1,21x
Nbr of Employees 235
Free-Float 50,6%
More Financials
Company
Oncodesign SA is a France-based company that discovers and develops therapies against cancer. The Company's services include target identification, validation and cellular screens; preclinical research, in vivo screening and pharmacology; molecular pharmacology and biomarkers, pharmaco-imaging and immunology, among others. Its activities include preclinical evaluation services and discovery operations. The Company's... 
More about the company
Ratings of ONCODESIGN
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about ONCODESIGN
07/22GLOBAL MARKETS LIVE : AT&T, American Airlines, Biogen, Netflix, ABB...
07/21Oncodesign Announces Unaudited Consolidated Turnover Results for the First Ha..
CI
07/05Oncodesign Appoints Aline Aubertin as New Independent Director
CI
07/05ONCODESIGN : Nomination
CO
06/28Oncodesign Announces a Strategic Collaboration Agreement with Covalab
CI
06/24GLOBAL MARKETS LIVE : Siemens, BHP Group, Visa, JP Morgan Chase, Proximus...
06/24ONCODESIGN : provides an update on its progress on RIPK2
PU
06/24Oncodesign Provides Update on Its Progress on RIPK2
CI
06/14Servier and Oncodesign Announce the Selection of a Preclinical Candidate as P..
CI
05/19GLOBAL MARKETS LIVE : Target, Take-Two, Google, KKR, JP Morgan....
05/18InterSystems and Oncodesign Partner for the Optimization of Data Use to Enhan..
CI
04/08Oncodesign Reports Consolidated Earnings Results for the Year Ended December ..
CI
02/15Oncodesign Société Anonyme commences an Equity Buyback Plan for 10% of its is..
CI
01/28ONCODESIGN : Maintains Its Revenue and Operating Income at €38 Million in 2020 a..
BU
01/28Oncodesign Société Anonyme Reports Unaudited Consolidated Revenue Results for..
CI
More news
News in other languages on ONCODESIGN
03:08aSTOCK MARKET PARIS : Même pas peur des quatre sorcières
02:34aEN DIRECT DES MARCHES : Renault, Unibail, Euronext, Amundi, Invesco, Ryanair, Gr..
07/22ONCODESIGN : forte augmentation du C.A. semestriel
07/22EN DIRECT DES MARCHES : Publicis, Soitec, Technip Energies, Ipsos, Novartis, Giv..
07/22STOCK MARKET PARIS : Une correction, quelle correction ?
More news
Chart ONCODESIGN
Duration : Period :
ONCODESIGN Technical Analysis Chart | ALONC | FR0011766229 | MarketScreener
Technical analysis trends ONCODESIGN
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 10,44 €
Average target price 16,60 €
Spread / Average Target 59,0%
EPS Revisions
Managers and Directors
Philippe Genne Chairman & Chief Executive Officer
Arnaud Lafforgue Chief Financial & Administrative Officer
Jan Hoflack Chief Scientific Officer
Francis Bichat Director-Technology
Stéphane Gerart Chief Information Officer
Sector and Competitors
1st jan.Capi. (M$)
ONCODESIGN-11.15%84
MODERNA, INC.321.80%175 368
LONZA GROUP AG34.92%61 973
IQVIA HOLDINGS INC.43.91%49 541
CELLTRION, INC.-25.63%31 848
SEAGEN INC.-12.32%27 670